Targeting hexokinase 2 (HK2), the first key enzyme in the process of glycolysis, or 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which produces fructose-2,6-bisphosphate, the most potent allosteric activator of the glycolytic rate-limiting enzyme phosphofructokinase-1, can alleviate TGF-β1-induced LF activation and lung fibrosis [3, 4]. This evidence concerns the gene HK2 and pulmonary fibrosis.